Purpose: The purpose of the present study was to investigate whether thrombomodulin (TM) prevents the development of pulmonary hypertension (PH) in monocrotaline (MCT)-injected rats.
Methods: Human recombinant TM (3 mg/kg/2 days) or saline were given to MCT-injected male Sprague-Dawley rats for 19 (n = 14) or 29 (n = 11) days. Control rats (n = 6) were run for 19 days. The mean pulmonary artery pressure (mPAP), right ventricular hypertrophy (RVH), percentages of muscularized peripheral arteries (%muscularization), and medial wall thickness of small muscular arteries (%MWT) were measured. To determine inflammatory and coagulation responses, broncho-alveolar lavage fluid (BALF) was analyzed in another set of rats (n = 29). Western blotting for endothelial nitric oxide synthase (eNOS) and phosphorylated eNOS (peNOS) in the lung tissue was performed in separate rats (n = 13). Survival was determined in 60 rats.
Results: MCT increased mPAP, RVH, %muscularization, and %MWT. TM treatment significantly reduced mPAP, %muscularization, and %MWT in peripheral arteries with an external diameter of 50-100 μm in 19 days after MCT injection, but the effect was lost after 29 days. MCT increased the levels of tumor necrosis factor alpha, monocyte chemoattractant protein-1, and thrombin-antithrombin complex in BALF. Expression of eNOS increased in MCT rats, while peNOS decreased. The relative amount of peNOS to total eNOS increased in MCT/TM rats compared to MCT/Vehicle rats. A Kaplan-Meier survival curve showed no difference with and without TM.
Conclusion: Although the administration of TM might slightly delay the progression of MCT-induced PH, the physiological significance for treatment is limited, since the survival rate was not improved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00540-013-1663-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary arterial hypertension-induced occlusion of left main coronary artery: pulmonary artery reconstruction surgery resolves stenosis indirectly.
J Invasive Cardiol
January 2025
Department of Echocardiography, Wuhan Asia Heart Hospital Affiliated to Wuhan University of Science and Technology. No.753 Jinghan Road, Hankou District, Wuhan, China. Email:
The burden of illness of the organ manifestations of systemic sclerosis: a pragmatic, targeted review.
Clin Exp Rheumatol
January 2025
Department of Medicine, Division of Rheumatology, University of California, Los Angeles, USA.
Objectives: This structured, targeted literature review aimed to assess the mortality, humanistic and economic burden of eight organ manifestations which are commonly experienced by systemic sclerosis patients.
Methods: Identification of relevant literature was carried out by searching in Ovid MEDLINE and EMBASE, PubMed, and NHS Economic Evaluation Database in August 2023. Studies reporting original data on patients with systemic sclerosis with at least one of eight organ manifestations (interstitial lung disease and/or pulmonary hypertension, skin, peripheral vascular, musculoskeletal, gastrointestinal, cardiac or renal involvement) published within the last 15 years were included.
Mortality Prediction in Newborns With Persistent Pulmonary Hypertension: A Comparison of Four Illness Severity Scores.
Pediatr Pulmonol
January 2025
Department of Pediatrics, Division of Neonatology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Objective: This study aimed to compare the accuracy of four neonatal illness severity scores for predicting mortality in persistent pulmonary hypertension of the newborn (PPHN).
Study Design: This retrospective study included neonates diagnosed with PPHN between 2013 and 2022. The illness severity scores of four commonly used tools were completed for each infant: the Clinical Risk Index for Babies-II (CRIB-II), the Score for Neonatal Acute Physiology-Perinatal Extension version II (SNAPPE-II) in the first 12 h after admission and maximum oxygenation index (OI) and Vasoactive-Inotropic score (VIS) during the first 24 h (OI24max and VIS24max), 48 h (OI48max and VIS48max), and 72 h (OI72max and VIS72max) after admission.
[A case of transcatheter membrane-covered stent shunt for severe pulmonary hypertension post-CHD surgery].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Department of Cardio-Thoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai200127, China.
Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age.
BMJ Open
December 2024
Research and Development Center for New Medical Frontiers, Department of Advanced Medicine, Division of Neonatal Intensive Care Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Objectives: Inhaled nitric oxide (iNO) is a known treatment for pulmonary hypertension (PH) associated with bronchopulmonary dysplasia in preterm infants after 7 days of age (postacute phase). However, a consensus regarding the optimal criteria for initiating iNO therapy in this population in the postacute phase is currently lacking. This study, therefore, aimed to identify the criteria for initiating iNO therapy, alongside the associated clinical and echocardiographic findings, in this population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!